Strategic Partnership
eTheRNA Announces Research Agreement with Merck KGaA, Darmstadt, Germany to Access mRNA Technologies
eTheRNA Immunotherapies NV
PR-M02-22-02Feb 03, 2022
Study
eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-Based Cancer Specific Immunotherapy (ECI-006) in Melanoma
eTheRNA Immunotherapies NV
PR-M05-18-NI-106May 29, 2018